Key Points
- Zai Lab director William Lis sold 8,506 shares at an average price of $25, reducing his position by 16.86% to 41,931 shares worth approximately $1.05 million.
- Zai Lab reported a quarterly loss of $0.50 per share on revenue of $106.31 million, with negative net margins and return on equity; analysts expect a full-year loss of $2.17 per share.
- Analyst sentiment remains mixed but leans positive, with a consensus “Moderate Buy” rating and a $40.20 target price versus the stock’s $26.03 opening price.
Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Get Free Report) CFO Yajing Chen sold 619 shares of Zai Lab stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.00, for a total transaction of $15,475.00. Following the completion of the transaction, the chief financial officer directly owned 35,072 shares in the company, valued at approximately $876,800. The trade was a 1.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Yajing Chen also recently made the following trade(s):
- On Friday, June 26th, Yajing Chen sold 2,264 shares of Zai Lab stock. The shares were sold at an average price of $17.46, for a total transaction of $39,529.44.
Zai Lab Stock Up 2.1%
Shares of Zai Lab stock opened at $26.03 on Friday. The company's fifty day simple moving average is $19.40 and its two-hundred day simple moving average is $19.44. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $36.77. The firm has a market cap of $2.96 billion, a PE ratio of -15.22 and a beta of 0.78.
Zai Lab (NASDAQ:ZLAB - Get Free Report) last issued its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) EPS for the quarter. The firm had revenue of $106.31 million for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. As a group, sell-side analysts expect that Zai Lab Limited Unsponsored ADR will post -2.17 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have commented on ZLAB. Wall Street Zen lowered Zai Lab from a "hold" rating to a "sell" rating in a research report on Saturday, May 16th. Zacks Research raised shares of Zai Lab from a "strong sell" rating to a "hold" rating in a research note on Tuesday, July 7th. Weiss Ratings raised Zai Lab from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 29th. Finally, Citigroup increased their target price on Zai Lab from $44.00 to $45.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.20.
View Our Latest Stock Report on ZLAB
Institutional Investors Weigh In On Zai Lab
An institutional investor recently raised its stake in Zai Lab stock. Royal Bank of Canada lifted its position in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB - Free Report) by 214.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,771 shares of the company's stock after acquiring an additional 9,390 shares during the period. Royal Bank of Canada's holdings in Zai Lab were worth $498,000 as of its most recent filing with the Securities & Exchange Commission. 41.65% of the stock is currently owned by institutional investors and hedge funds.
Zai Lab Company Profile
(
Get Free Report)
Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company's end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.
The company's marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton's tyrosine kinase inhibitor approved for several B-cell malignancies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
